Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 95 entries
Sorted by: Best Match Show Resources per page
Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular mechanisms.

Genetics research international

Vanderschuren KL, Sieverink T, Wilders R.
PMID: 24416594
Genet Res Int. 2013;2013:460805. doi: 10.1155/2013/460805. Epub 2013 Dec 12.

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy associated with cardiac arrhythmias originating in the right ventricle, heart failure, and sudden cardiac death. Development of ARVD/C type 1 has been attributed to differential expression of transforming growth factor...

Cite
Vanderschuren KL, Sieverink T, Wilders R. Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular mechanisms. Genet Res Int. 2013;2013:460805doi: 10.1155/2013/460805.
Vanderschuren, K. L., Sieverink, T., & Wilders, R. (2013). Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular mechanisms. Genetics research international, 2013460805. https://doi.org/10.1155/2013/460805
Vanderschuren, Koen L A, et al. "Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular mechanisms." Genetics research international vol. 2013 (2013): 460805. doi: https://doi.org/10.1155/2013/460805
Vanderschuren KL, Sieverink T, Wilders R. Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular mechanisms. Genet Res Int. 2013;2013:460805. doi: 10.1155/2013/460805. Epub 2013 Dec 12. PMID: 24416594; PMCID: PMC3876595.
Copy Download .nbib Format: NLM
Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies.

JAMA network open

Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC.
PMID: 34748007
JAMA Netw Open. 2021 Nov 01;4(11):e2133205. doi: 10.1001/jamanetworkopen.2021.33205.

IMPORTANCE: Precision oncology is revolutionizing cancer care, allowing for personalized treatments to improve outcomes. Cancer research has benefitted from well-designed studies incorporating precision medicine objectives, but it is unclear if these studies are representative of the diverse cancer population.OBJECTIVE:...

Cite
Aldrighetti CM, Niemierko A, Van Allen E, et al. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Netw Open. 2021;4(11):e2133205doi: 10.1001/jamanetworkopen.2021.33205.
Aldrighetti, C. M., Niemierko, A., Van Allen, E., Willers, H., & Kamran, S. C. (2021). Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA network open, 4(11), e2133205. https://doi.org/10.1001/jamanetworkopen.2021.33205
Aldrighetti, Christopher M, et al. "Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies." JAMA network open vol. 4,11 (2021): e2133205. doi: https://doi.org/10.1001/jamanetworkopen.2021.33205
Aldrighetti CM, Niemierko A, Van Allen E, Willers H, Kamran SC. Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Netw Open. 2021 Nov 01;4(11):e2133205. doi: 10.1001/jamanetworkopen.2021.33205. PMID: 34748007; PMCID: PMC8576580.
Copy Download .nbib Format: NLM
Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.

JAMA oncology

Kamran SC, Yeap BY, Ulysse CA, Cronin C, Bowes CL, Durgin B, Gainor JF, Khandekar MJ, Tansky JY, Keane FK, Olsen CC, Willers H.
PMID: 33830168
JAMA Oncol. 2021 Jun 01;7(6):910-914. doi: 10.1001/jamaoncol.2021.0281.

IMPORTANCE: Severe acute esophagitis occurs in up to 20% of patients with locally advanced lung cancer treated with chemoradiation therapy to at least 60 Gy once daily and represents a dose-limiting toxic event associated with poor outcomes.OBJECTIVE: To assess...

Cite
Kamran SC, Yeap BY, Ulysse CA, et al. Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2021;7(6):910-914doi: 10.1001/jamaoncol.2021.0281.
Kamran, S. C., Yeap, B. Y., Ulysse, C. A., Cronin, C., Bowes, C. L., Durgin, B., Gainor, J. F., Khandekar, M. J., Tansky, J. Y., Keane, F. K., Olsen, C. C., & Willers, H. (2021). Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial. JAMA oncology, 7(6), 910-914. https://doi.org/10.1001/jamaoncol.2021.0281
Kamran, Sophia C, et al. "Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial." JAMA oncology vol. 7,6 (2021): 910-914. doi: https://doi.org/10.1001/jamaoncol.2021.0281
Kamran SC, Yeap BY, Ulysse CA, Cronin C, Bowes CL, Durgin B, Gainor JF, Khandekar MJ, Tansky JY, Keane FK, Olsen CC, Willers H. Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jun 01;7(6):910-914. doi: 10.1001/jamaoncol.2021.0281. PMID: 33830168; PMCID: PMC8033505.
Copy Download .nbib Format: NLM
Cancer and Aging: Two Tightly Interconnected Biological Processes.

Cancers

Berben L, Floris G, Wildiers H, Hatse S.
PMID: 33808654
Cancers (Basel). 2021 Mar 19;13(6). doi: 10.3390/cancers13061400.

Age is one of the main risk factors of cancer; several biological changes linked with the aging process can explain this. As our population is progressively aging, the proportion of older patients with cancer is increasing significantly. Due to...

Cite
Berben L, Floris G, Wildiers H, et al. Cancer and Aging: Two Tightly Interconnected Biological Processes. Cancers (Basel). 2021;13(6)doi: 10.3390/cancers13061400.
Berben, L., Floris, G., Wildiers, H., & Hatse, S. (2021). Cancer and Aging: Two Tightly Interconnected Biological Processes. Cancers, 13(6), . https://doi.org/10.3390/cancers13061400
Berben, Lieze, et al. "Cancer and Aging: Two Tightly Interconnected Biological Processes." Cancers vol. 13,6 (2021). doi: https://doi.org/10.3390/cancers13061400
Berben L, Floris G, Wildiers H, Hatse S. Cancer and Aging: Two Tightly Interconnected Biological Processes. Cancers (Basel). 2021 Mar 19;13(6). doi: 10.3390/cancers13061400. PMID: 33808654; PMCID: PMC8003441.
Copy Download .nbib Format: NLM
Targeted Therapies in Older Adults With Solid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Battisti NML, Decoster L, Williams GR, Kanesvaran R, Wildiers H, Ring A.
PMID: 34043448
J Clin Oncol. 2021 Jul 01;39(19):2128-2137. doi: 10.1200/JCO.21.00132. Epub 2021 May 27.

No abstract available.

Cite
Battisti NML, Decoster L, Williams GR, et al. Targeted Therapies in Older Adults With Solid Tumors. J Clin Oncol. 2021;39(19):2128-2137doi: 10.1200/JCO.21.00132.
Battisti, N. M. L., Decoster, L., Williams, G. R., Kanesvaran, R., Wildiers, H., & Ring, A. (2021). Targeted Therapies in Older Adults With Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(19), 2128-2137. https://doi.org/10.1200/JCO.21.00132
Battisti, Nicolò Matteo Luca, et al. "Targeted Therapies in Older Adults With Solid Tumors." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,19 (2021): 2128-2137. doi: https://doi.org/10.1200/JCO.21.00132
Battisti NML, Decoster L, Williams GR, Kanesvaran R, Wildiers H, Ring A. Targeted Therapies in Older Adults With Solid Tumors. J Clin Oncol. 2021 Jul 01;39(19):2128-2137. doi: 10.1200/JCO.21.00132. Epub 2021 May 27. PMID: 34043448; PMCID: PMC8260907.
Copy Download .nbib Format: NLM
Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home.

BMC nursing

Coolbrandt A, Wildiers H, Aertgeerts B, Dierckx de Casterlé B, van Achterberg T, Milisen K.
PMID: 29983638
BMC Nurs. 2018 Jun 27;17:28. doi: 10.1186/s12912-018-0297-8. eCollection 2018.

BACKGROUND: Given the great symptom burden associated with chemotherapy on the one hand and generally poor self-management of symptoms by cancer patients on the other hand, our aim was to develop a nursing intervention to reduce symptom burden in...

Cite
Coolbrandt A, Wildiers H, Aertgeerts B, et al. Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home. BMC Nurs. 2018;17:28doi: 10.1186/s12912-018-0297-8.
Coolbrandt, A., Wildiers, H., Aertgeerts, B., Dierckx de Casterlé, B., van Achterberg, T., & Milisen, K. (2018). Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home. BMC nursing, 1728. https://doi.org/10.1186/s12912-018-0297-8
Coolbrandt, Annemarie, et al. "Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home." BMC nursing vol. 17 (2018): 28. doi: https://doi.org/10.1186/s12912-018-0297-8
Coolbrandt A, Wildiers H, Aertgeerts B, Dierckx de Casterlé B, van Achterberg T, Milisen K. Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home. BMC Nurs. 2018 Jun 27;17:28. doi: 10.1186/s12912-018-0297-8. eCollection 2018. PMID: 29983638; PMCID: PMC6020323.
Copy Download .nbib Format: NLM
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.

Cancers

Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D.
PMID: 34503231
Cancers (Basel). 2021 Sep 01;13(17). doi: 10.3390/cancers13174421.

Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin...

Cite
Schettini F, Giuliano M, Lambertini M, et al. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174421.
Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., Onesti, C. E., Harbeck, N., Lüftner, D., Rottey, S., van Dam, P. A., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., Tjan-Heijnen, V. C. G., Cortes, J., Locci, M., Paris, I., Del Mastro, L., De Placido, S., Martín, M., Jerusalem, G., Venturini, S., Curigliano, G., & Generali, D. (2021). Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 13(17), . https://doi.org/10.3390/cancers13174421
Schettini, Francesco, et al. "Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174421
Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers (Basel). 2021 Sep 01;13(17). doi: 10.3390/cancers13174421. PMID: 34503231; PMCID: PMC8430783.
Copy Download .nbib Format: NLM
Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF.
PMID: 34752147
J Clin Oncol. 2022 Jan 01;40(1):12-23. doi: 10.1200/JCO.21.01891. Epub 2021 Nov 09.

PURPOSE: The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood.METHODS: We performed a prospective cohort study of adults with solid-organ or hematologic cancers to evaluate anti-SARS-CoV-2 immunoglobulin A/M/G spike antibodies, neutralization, and reactogenicity ≥...

Cite
Naranbhai V, Pernat CA, Gavralidis A, et al. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2021;40(1):12-23doi: 10.1200/JCO.21.01891.
Naranbhai, V., Pernat, C. A., Gavralidis, A., St Denis, K. J., Lam, E. C., Spring, L. M., Isakoff, S. J., Farmer, J. R., Zubiri, L., Hobbs, G. S., How, J., Brunner, A. M., Fathi, A. T., Peterson, J. L., Sakhi, M., Hambelton, G., Denault, E. N., Mortensen, L. J., Perriello, L. A., Bruno, M. N., Bertaux, B. Y., Lawless, A. R., Jackson, M. A., Niehoff, E., Barabell, C., Nambu, C. N., Nakajima, E., Reinicke, T., Bowes, C., Berrios-Mairena, C. J., Ofoman, O., Kirkpatrick, G. E., Thierauf, J. C., Reynolds, K., Willers, H., Beltran, W. G., Dighe, A. S., Saff, R., Blumenthal, K., Sullivan, R. J., Chen, Y. B., Kim, A., Bardia, A., Balazs, A. B., Iafrate, A. J., & Gainor, J. F. (2022). Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(1), 12-23. https://doi.org/10.1200/JCO.21.01891
Naranbhai, Vivek, et al. "Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 40,1 (2022): 12-23. doi: https://doi.org/10.1200/JCO.21.01891
Naranbhai V, Pernat CA, Gavralidis A, St Denis KJ, Lam EC, Spring LM, Isakoff SJ, Farmer JR, Zubiri L, Hobbs GS, How J, Brunner AM, Fathi AT, Peterson JL, Sakhi M, Hambelton G, Denault EN, Mortensen LJ, Perriello LA, Bruno MN, Bertaux BY, Lawless AR, Jackson MA, Niehoff E, Barabell C, Nambu CN, Nakajima E, Reinicke T, Bowes C, Berrios-Mairena CJ, Ofoman O, Kirkpatrick GE, Thierauf JC, Reynolds K, Willers H, Beltran WG, Dighe AS, Saff R, Blumenthal K, Sullivan RJ, Chen YB, Kim A, Bardia A, Balazs AB, Iafrate AJ, Gainor JF. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. J Clin Oncol. 2022 Jan 01;40(1):12-23. doi: 10.1200/JCO.21.01891. Epub 2021 Nov 09. PMID: 34752147; PMCID: PMC8683230.
Copy Download .nbib Format: NLM
Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Bowes CL, Naranbhai V, St Denis KJ, Lam EC, Bertaux B, Keane FK, Khandekar MJ, Balazs AB, Iafrate JA, Gainor JF, Willers H.
PMID: 34838892
Radiother Oncol. 2021 Nov 25;166:88-91. doi: 10.1016/j.radonc.2021.11.012. Epub 2021 Nov 25.

The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody...

Cite
Bowes CL, Naranbhai V, St Denis KJ, et al. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiother Oncol. 2021;166:88-91doi: 10.1016/j.radonc.2021.11.012.
Bowes, C. L., Naranbhai, V., St Denis, K. J., Lam, E. C., Bertaux, B., Keane, F. K., Khandekar, M. J., Balazs, A. B., Iafrate, J. A., Gainor, J. F., & Willers, H. (2021). Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 16688-91. https://doi.org/10.1016/j.radonc.2021.11.012
Bowes, Cynthia L, et al. "Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 166 (2021): 88-91. doi: https://doi.org/10.1016/j.radonc.2021.11.012
Bowes CL, Naranbhai V, St Denis KJ, Lam EC, Bertaux B, Keane FK, Khandekar MJ, Balazs AB, Iafrate JA, Gainor JF, Willers H. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy. Radiother Oncol. 2021 Nov 25;166:88-91. doi: 10.1016/j.radonc.2021.11.012. Epub 2021 Nov 25. PMID: 34838892; PMCID: PMC8613981.
Copy Download .nbib Format: NLM
Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.

ESMO open

Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H.
PMID: 34924144
ESMO Open. 2021 Dec;6(6):100219. doi: 10.1016/j.esmoop.2021.100219. Epub 2021 Sep 16.

BACKGROUND: With the implementation of multidisciplinary treatment and development of multiple novel anticancer drugs in parallel with expanding knowledge of supportive and palliative care, a need for separate training and specialisation in medical oncology emerged. A Global Curriculum (GC)...

Cite
Cufer T, Kosty M, Osterlund P, et al. Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey. ESMO Open. 2021;6(6):100219doi: 10.1016/j.esmoop.2021.100219.
Cufer, T., Kosty, M., Osterlund, P., Jezdic, S., Pyle, D., Awada, A., Close, J., El-Saghir, N., Lordick, F., Rutkowski, P., Tfayli, A., & Wildiers, H. (2021). Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey. ESMO open, 6(6), 100219. https://doi.org/10.1016/j.esmoop.2021.100219
Cufer, T, et al. "Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey." ESMO open vol. 6,6 (2021): 100219. doi: https://doi.org/10.1016/j.esmoop.2021.100219
Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H. Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey. ESMO Open. 2021 Dec;6(6):100219. doi: 10.1016/j.esmoop.2021.100219. Epub 2021 Sep 16. PMID: 34924144.
Copy Download .nbib Format: NLM
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline .

Therapeutic advances in medical oncology

Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V.
PMID: 34917174
Ther Adv Med Oncol. 2021 Dec 09;13:17588359211059601. doi: 10.1177/17588359211059601. eCollection 2021.

PURPOSE: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline PATIENTS AND METHODS: In this phase-3, double-blind, placebo-controlled trial, patients (RESULTS: In the intention-to-treat population, there...

Cite
Ayoub JP, Wildiers H, Friedlander M, et al. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline . Ther Adv Med Oncol. 2021;13:17588359211059601doi: 10.1177/17588359211059601.
Ayoub, J. P., Wildiers, H., Friedlander, M., Arun, B. K., Han, H. S., Puhalla, S., Shparyk, Y., Jakobsen, E. H., Wu, M., Bach, B. A., Feng, D., Ratajczak, C. K., Maag, D., & Diéras, V. (2021). Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline . Therapeutic advances in medical oncology, 1317588359211059601. https://doi.org/10.1177/17588359211059601
Ayoub, Jean-Pierre, et al. "Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline ." Therapeutic advances in medical oncology vol. 13 (2021): 17588359211059601. doi: https://doi.org/10.1177/17588359211059601
Ayoub JP, Wildiers H, Friedlander M, Arun BK, Han HS, Puhalla S, Shparyk Y, Jakobsen EH, Wu M, Bach BA, Feng D, Ratajczak CK, Maag D, Diéras V. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline . Ther Adv Med Oncol. 2021 Dec 09;13:17588359211059601. doi: 10.1177/17588359211059601. eCollection 2021. PMID: 34917174; PMCID: PMC8669119.
Copy Download .nbib Format: NLM
[No title available]

Pharmaceutics

Velasco-Ruiz A, Nuñez-Torres R, Pita G, Wildiers H, Lambrechts D, Hatse S, Delombaerde D, Van Brussel T, Alonso MR, Alvarez N, Herraez B, Vulsteke C, Zamora P, Lopez-Fernandez T, Gonzalez-Neira A.
PMID: 34834357
Pharmaceutics. 2021 Nov 16;13(11). doi: 10.3390/pharmaceutics13111942.

Anthracyclines are among the most used chemotherapeutic agents in breast cancer (BC). However their use is hampered by anthracycline-induced cardiotoxicity (AIC). The currently known clinical and genetic risk factors do not fully explain the observed inter-individual variability and only...

Cite
Velasco-Ruiz A, Nuñez-Torres R, Pita G, et al. . Pharmaceutics. 2021;13(11)doi: 10.3390/pharmaceutics13111942.
Velasco-Ruiz, A., Nuñez-Torres, R., Pita, G., Wildiers, H., Lambrechts, D., Hatse, S., Delombaerde, D., Van Brussel, T., Alonso, M. R., Alvarez, N., Herraez, B., Vulsteke, C., Zamora, P., Lopez-Fernandez, T., & Gonzalez-Neira, A. (2021). . Pharmaceutics, 13(11), . https://doi.org/10.3390/pharmaceutics13111942
Velasco-Ruiz, Alejandro, et al. "." Pharmaceutics vol. 13,11 (2021). doi: https://doi.org/10.3390/pharmaceutics13111942
Velasco-Ruiz A, Nuñez-Torres R, Pita G, Wildiers H, Lambrechts D, Hatse S, Delombaerde D, Van Brussel T, Alonso MR, Alvarez N, Herraez B, Vulsteke C, Zamora P, Lopez-Fernandez T, Gonzalez-Neira A. . Pharmaceutics. 2021 Nov 16;13(11). doi: 10.3390/pharmaceutics13111942. PMID: 34834357; PMCID: PMC8622627.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 95 entries